Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: CapecitabineRadiation: Standard Dose Acclerated Fraction Radiotherapy
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2011-04-11
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 35
- Registration Number
- NCT01333332
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors
- Conditions
- Solid Cancers
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01332604
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
- First Posted Date
- 2011-03-31
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Tracon Pharmaceuticals Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT01326481
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Confirmation Study of Eribulin in Combination With Capecitabine
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 76
- Registration Number
- NCT01323530
Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer
- Conditions
- CRC
- Interventions
- First Posted Date
- 2011-03-03
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 2000
- Registration Number
- NCT01308086
- Locations
- 🇬🇷
University Hospital of Crete, Dep of Medical Oncology, Heraklion, Greece
Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma
- Conditions
- Stage II Rectal CancerStage III Rectal Cancer
- Interventions
- Drug: CapecitabineDrug: 5-FUDrug: LeucovorinDrug: OxaliplatinRadiation: radiationProcedure: total mesorectal excision
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT01302613
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT01300962
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas
- Conditions
- Pancreatic Cancer
- Interventions
- Biological: ganitumabDrug: capecitabineDrug: gemcitabine hydrochlorideRadiation: 3-dimensional conformal radiation therapy
- First Posted Date
- 2011-02-17
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 8
- Registration Number
- NCT01298401
- Locations
- 🇺🇸
CCOP - Christiana Care Health Services, Newark, Delaware, United States
🇺🇸James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
🇺🇸James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States
Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer
- Conditions
- Adenocarcinoma
- Interventions
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT01295086
- Locations
- 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇩🇰Aarhus University Hospital, Aarhus, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: fluorouracilDrug: leucovorin calciumDrug: oxaliplatinDrug: irinotecan hydrochlorideDrug: capecitabineGenetic: mutation analysisBiological: bevacizumabBiological: cetuximabGenetic: gene expression analysisOther: laboratory biomarker analysisOther: immunohistochemistry staining methodGenetic: nucleic acid sequencingGenetic: protein expression analysisGenetic: polymerase chain reactionGenetic: DNA analysis
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01280643
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.